Catalyst

Slingshot members are tracking this event:

Anti-Cancer Agent “Xeloda”, Obtained Approval for Additional Indication of “Adjuvant Chemotherapy for Rectal Cancer”

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
RHHBY

100%

Additional Information

Additional Relevant Details  The “Review Committee on Unapproved Drugs and Indications with High Medical Needs” was established for the purpose of enhancing development by the pharmaceutical companies of drugs and indications that have been approved for use in western countries but not yet approved in Japan, through activities such as evaluating medical needs and confirming the applicability of “public knowledge-based application” and investigating the need for studies that should be additionally conducted. 
http://www.roche.com...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 26, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Xeloda, Rectal Cancer, Adjuvant Chemotherapy